Skip to content
Peptigraph home

Tirzepatide for Heart Health: What the Evidence Shows

What human and animal studies show about Tirzepatide for heart health, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP dual agonistUpdated
Strongest evidence
Human RCT
Human studies
358
PubMed records, our ledger
Animal studies
11
PubMed records, our ledger
Studies we summarised
7
with an outcome for heart health

Evidence for heart health

Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Tirzepatide for heart health: outcomes in published studies
OutcomeResultStudy typeSource
Cardiovascular death, MI or strokePrimary events occurred in 12.2% (tirzepatide) vs 13.1% (dulaglutide); hazard ratio 0.92 (95.3% CI 0.83 to 1.01), noninferior but superiority not shown (P = 0.09).Human RCTn = 13165The New England journal of medicine 2025, PMID 41406444
Cardiovascular death or worsening heart failureThe composite occurred in 9.9% on tirzepatide vs 15.3% on placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95).Human RCTn = 731The New England journal of medicine 2025, PMID 39555826
Quality of life (KCCQ-CSS)The symptom score improved by 19.5 with tirzepatide vs 12.7 with placebo, a difference of 6.9 (95% CI 3.3 to 10.6).Human RCTn = 731The New England journal of medicine 2025, PMID 39555826
Blood pressureBy 72 weeks, blood pressure was 6.8 mm Hg systolic and 4.2 mm Hg diastolic lower than with placebo.Human RCTHeart 2024, PMID 39084707
Role of weight lossWeight loss explained 68% of the systolic and 71% of the diastolic blood pressure reduction.Human RCTHeart 2024, PMID 39084707
Triglycerides and metabolitesTriglycerides and diglycerides were lowered significantly versus baseline, dulaglutide and placebo (post hoc analysis).Human RCTn = 259The Journal of clinical endocrinology and metabolism 2022, PMID 34608929
Major adverse cardiovascular eventsMACE-4 events were not increased on tirzepatide versus glargine (hazard ratio 0·74, 95% CI 0·51-1·08).Human RCTn = 1995Lancet 2021, PMID 34672967
Systolic blood pressureSystolic blood pressure fell by a median of 4.20 (5 mg), 5.34 (10 mg) and 5.77 mmHg (15 mg).Meta-analysisDiabetes, obesity & metabolism 2023, PMID 37700437
Total cholesterolTotal cholesterol fell by a median of 3.76% (5 mg), 4.63% (10 mg) and 5.93% (15 mg).Meta-analysisDiabetes, obesity & metabolism 2023, PMID 37700437
Lipid fractionsTirzepatide raised HDL cholesterol and lowered LDL cholesterol and triglycerides.Meta-analysisDiabetes, obesity & metabolism 2023, PMID 37700437
Major adverse cardiovascular eventsHazard ratios versus controls were 0.80 (95% CI 0.57-1.11) for the four-component cardiovascular composite, 0.90 for cardiovascular death and 0.80 for all-cause death; none were statistically significant.Meta-analysisNature medicine 2022, PMID 35210595

PubMed records for Tirzepatide and heart health: 358 human, 11 animal (search counts, not studies we reviewed). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 41406444

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Blood pressure

MedlinePlus defines blood pressure as the force of blood pushing against the walls of your arteries.[8]

In SURMOUNT-1 people on tirzepatide had a net systolic fall of 6.8 mm Hg and diastolic fall of 4.2 mm Hg versus placebo at week 72.[3]

The mediation analysis attributed 68% of the systolic change to weight loss.[3]

A pooled analysis of randomised trials put the systolic fall at 4.20, 5.34 and 5.77 mmHg for 5, 10 and 15 mg.[6]

Cholesterol

MedlinePlus describes cholesterol as a waxy, fat-like substance in all your cells, and warns that too much can form plaque in arteries.[9]

The same meta-analysis found total cholesterol fell by 3.76%, 4.63% and 5.93% at 5, 10 and 15 mg, with LDL and triglycerides lower and HDL higher.[6]

Heart outcomes

In SUMMIT, people with heart failure with preserved ejection fraction and obesity had fewer cardiovascular deaths or worsening heart-failure events on tirzepatide, 9.9% versus 15.3%.[2]

In people with type 2 diabetes and atherosclerotic disease, SURPASS-CVOT found tirzepatide non-inferior to dulaglutide for death, heart attack or stroke, with a hazard ratio of 0.92.[1]

The Zepbound label notes a mean heart rate increase of 1 to 3 beats per minute with treatment versus no increase on placebo.[10]

Other peptides people research for heart health

All peptides for heart health, compared

Common questions

Does Tirzepatide help with heart health?

The strongest study we summarise for heart health is human rct evidence, across 7 studies with an outcome for heart health. A trial result is not an approval; see the legal status.

Is Tirzepatide approved for heart health?

Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for heart health?

There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.

Does tirzepatide lower blood pressure?

In the SURMOUNT-1 post hoc analysis systolic pressure fell 6.8 mm Hg more than on placebo, mainly through weight loss.[3]

Does tirzepatide lower cholesterol?

Total cholesterol fell by 3.76% to 5.93% across doses in a meta-analysis, along with LDL and triglycerides.[6]

Is tirzepatide good for the heart?

It reduced the combined heart-failure endpoint in SUMMIT, but in diabetes it was only shown non-inferior to dulaglutide for major cardiovascular events.[2]

More on Tirzepatide

Sources

  1. 1Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
  2. 2Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2025PMID 39555826Accessed 2 Oct 2026
  3. 3Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.Heart (British Cardiac Society) · 2024PMID 39084707Accessed 2 Oct 2026
  4. 4Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022PMID 34608929Accessed 2 Oct 2026
  5. 5Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.Lancet (London, England) · 2021PMID 34672967Accessed 2 Oct 2026
  6. 6Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.Diabetes, obesity & metabolism · 2023PMID 37700437Accessed 2 Oct 2026
  7. 7Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.Nature medicine · 2022PMID 35210595Accessed 2 Oct 2026
  8. 8Official web pageOfficial web page · web page
  9. 9Official web pageOfficial web page · web page
  10. 10ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.